New Study Addresses ‘$28 Billion Problem’ of Research Fidelity
In the U.S. alone, around $28 billion a year is spent on preclinical research that is not reproducible, and low reproducibility rates contribute to both delays and costs of therapeutic drug development.
In the U.S. alone, around $28 billion a year is spent on preclinical research that is not reproducible, and low reproducibility rates contribute to both delays and costs of therapeutic drug development, according to a study published on June 9th, 2015 in the PLOS Biology journal by the Global Biological Standards Institute (GBSI) and two economists.
Analysis of past life science research studies indicates that the cumulative prevalence of irreproducible preclinical research exceeds 50%, and action is now required, noted the three authors, Drs. Leonard P. Freedman, Iain M. Cockburn and Timothy S. Simcoe.
"To achieve greatest levels of reproducibility, The Economics of Reproducibility in Preclinical Research offers tangible solutions - providing guidelines for advancing education and training and applying best practices in life science research. The valuable time, money and resources saved will mean finding faster treatments and cures," stated Freedman, who is president of GBSI.
Reviewing publicly available data from government sources, industry and analyst reports and scientific articles, the authors conducted an in-depth analysis of the key components of irreproducibility and used secondary research to benchmark the potential impact of improved standards. They think the causes of irreproducible research can be grouped into four categories: biological reagents and reference materials, study design, data analysis and reporting, and laboratory protocols. Of these, errors in biological reagents and materials (36% of total) and study design (28% of total) are the two largest factors.
By categorizing the root causes of irreproducibility and estimating their relative importance, it is possible to prioritize potential solutions, and ultimately, increase the overall return on public and private investments in research and development, they explained.
"Improving reproducibility levels will require a measured investment in time and resources," noted Cockburn. "We recommend investing in practical solutions and taking immediate steps in the areas where there will be the greatest return on investment."
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
